News
- Author:
- Ted Bosworth
Publish date: April 23, 2024
A newly completed trial has led to market withdrawal of the ALS therapy PB&TURSO.
News
- Author:
- Ted Bosworth
Publish date: April 23, 2024
Efgartigimod PC20 trial meets the primary endpoint with favorable safety profile.
News
- Author:
- Ted Bosworth
Publish date: April 22, 2024
Procedure that lifts prostate tissue improved symptoms and patient satisfaction compared with tissue ablation.
News
- Author:
- Ted Bosworth
Publish date: April 22, 2024
New data “suggest that meticulous follow-up is needed over a longer time” than previous studies have shown.
News
- Author:
- Ted Bosworth
Publish date: April 17, 2024
New data show little late benefit, but lecanemab is active when tau is low.
News
- Author:
- Ted Bosworth
Publish date: April 16, 2024
After a long career that has included participation in a series of promising but failed treatment trials for ALS, a prominent researcher has decide...
News
- Author:
- Ted Bosworth
Publish date: April 15, 2024
Some newer antidiabetic therapies provide protection against stroke even though their glycemic control is no better than the agents that have no su...
News
- Author:
- Ted Bosworth
Publish date: April 12, 2024
Delayed but clinically significant responses are seen a year or more after starting JAK inhibitors for alopecia areata.
News
- Author:
- Ted Bosworth
Publish date: April 10, 2024
Antisense treatment that inhibits ApoC-III expression can significantly reduce triglyceride, trial finds.
News
- Author:
- Ted Bosworth
Publish date: April 8, 2024
In one study, the addition of narrow-band ultraviolet-B light therapy to ritlecitinib appears more effective than ritlecitinib alone.
News
- Author:
- Ted Bosworth
Publish date: March 22, 2024
To date, "there is not much transparency in what data AI models are using," according to Dr. Veronica Rotemberg.
News
- Author:
- Ted Bosworth
Publish date: March 22, 2024
The 52-week analysis included 307 patients on continuous nemolizumab and 174 patients randomized previously to placebo and were nemolizumab-naive w...
News
- Author:
- Ted Bosworth
Publish date: March 18, 2024
Longer follow up is with the IL-17 inhibitor bimekizumab. In a 4-year open-label extension study, the PASI 90 rate was approximately 85% in treated...
Article
- Author:
- Ted Bosworth
Publish date: March 15, 2024
The phase 3 MS trial of the BTK inhibitor evobrutinib was not superior to teriflunomide for any endpoint.<...
News
- Author:
- Ted Bosworth
Publish date: March 15, 2024
At interim analysis, a stem cell extension study shows favorable clinical and biomarker effects for progressive MS.
